Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories
Gilead Sciences Inc. reported better-than-expected earnings for the first quarter of the year on Thursday and detailed more of its work on remdesivir, an antiviral COVID-19 drug candidate.